BIVI BioVie Inc. Stock Quote

BIVI [NASD]

Index	-	P/E	-	EPS (ttm)	-9.05	Insider Own	0.40%	Shs Outstand	24.98M	Perf Week	-11.81%
Market Cap	65.00M	Forward P/E	-	EPS next Y	-2.37	Insider Trans	1.99%	Shs Float	5.06M	Perf Month	-36.50%
Income	-149.50M	PEG	-	EPS next Q	-0.42	Inst Own	6.30%	Short Float	2.41%	Perf Quarter	-18.85%
Sales	-	P/S	-	EPS this Y	-116.30%	Inst Trans	-8.04%	Short Ratio	3.19	Perf Half Y	-55.44%
Book/sh	0.40	P/B	6.35	EPS next Y	-39.10%	ROA	-694.80%	Target Price	13.67	Perf Year	-82.35%
Cash/sh	0.96	P/C	2.65	EPS next 5Y	-	ROE	-	52W Range	2.51 - 19.10	Perf YTD	-43.56%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-86.70%	Beta	2.33
Dividend %	-	Quick Ratio	5.70	Sales past 5Y	-	Gross Margin	-	52W Low	1.20%	ATR	0.28
Employees	6	Current Ratio	5.70	Sales Q/Q	-	Oper. Margin	-	RSI (14)	27.54	Volatility	8.52% 8.56%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-31.10%	Profit Margin	-	Rel Volume	0.47	Prev Close	2.52
Shortable	Yes	LT Debt/Eq	1.16	Earnings	-	Payout	-	Avg Volume	38.18K	Price	2.54
Recom	1.70	SMA20	-18.51%	SMA50	-33.34%	SMA200	-50.30%	Volume	18,131	Change	0.79%

Jan-15-21

Initiated

B. Riley Securities

Buy

$47

Apr-25-22 08:00AM	BioVie to Participate at the B. Riley Securities Neuro & Ophthalmology Conference GlobeNewswire
Mar-29-22 10:55AM	These 2 Penny Stocks Are on Track for Massive Gains, Says Oppenheimer TipRanks +15.48%
Mar-10-22 08:00AM	BioVie Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report® GlobeNewswire
Mar-09-22 04:05PM	BioVie to Participate at the Oppenheimer Virtual Annual Healthcare Conference GlobeNewswire
Jan-20-22 08:00AM	BioVie Announces Treatment of First Patient in Phase 2 Clinical Trial of NE3107 for the Treatment of Parkinsons Disease GlobeNewswire
Jan-07-22 09:40AM	Has Biocept, Inc. (BIOC) Outpaced Other Medical Stocks This Year? Zacks -6.87%
Dec-28-21 08:00AM	BioVie to Participate at the LifeSci Partners 11th Annual Corporate Access Event GlobeNewswire
Dec-09-21 08:00AM	BioVie Announces Partnership with the American Liver Foundation GlobeNewswire
Dec-01-21 08:00AM	BioVie Secures Up to a $25.0 Million Debt Facility with Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P. GlobeNewswire -8.23%
Nov-04-21 08:00AM	BioVie Hosting Key Opinion Leader Webinar on Complications of Advanced Liver Cirrhosis and BIV201 Phase 2b Clinical Trial Update GlobeNewswire
Nov-01-21 08:00AM	BioVie Announces the Appointment of a New Chief Medical Officer GlobeNewswire +7.84%
Oct-26-21 08:00AM	BioVie Announces FDA Authorization to Initiate Phase 2 Trials Assessing NE3107s Pro-motoric Activity in Parkinsons Disease GlobeNewswire +21.61%
Oct-13-21 08:00AM	BioVie Hosting Key Opinion Leader Webinar on Neuroinflammation and Insulin Resistance and New Treatment Approaches for Alzheimers Disease GlobeNewswire
Sep-22-21 08:00AM	BioVie to Present at Cantor Virtual Global Healthcare Conference GlobeNewswire
Sep-15-21 04:01PM	BioVie to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Virtual Summit GlobeNewswire
Aug-11-21 01:14PM	BioVie Inc. Announces Closing of Public Offering of Common Stock GlobeNewswire
Aug-08-21 09:28PM	BioVie Inc. Announces Pricing of Public Offering of Common Stock GlobeNewswire
Aug-06-21 05:30PM	BioVie Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire -6.03%
Aug-05-21 08:00AM	BioVie Announces First Patient Enrolled in Phase 3 Study of NE3107 in Alzheimers Disease GlobeNewswire
Jul-27-21 08:00AM	BioVie Presents Data Supporting use of NE3107 in the Treatment of Alzheimers Disease at 2021 Alzheimers Association International Conference GlobeNewswire
Jul-22-21 08:00AM	BioVie to Present Rationale for use of NE3107 for the Treatment of Alzheimers Disease at 2021 Alzheimers Association International Conference GlobeNewswire
Jul-16-21 08:00AM	Basis for BioVies Phase 3 Clinical Trial of NE3107 in the Treatment of Alzheimers Disease Published in Neurodegenerative Disease Management GlobeNewswire
Jun-29-21 08:00AM	Development of BioVies NE3107 Asset Featured by the American Diabetes Association GlobeNewswire
Jun-28-21 08:00AM	BioVie Added to Russell Microcap® Index GlobeNewswire
Jun-25-21 08:00AM	BioVie Interview to Air on Bloomberg Television U.S. on the RedChip Money Report® GlobeNewswire
Jun-24-21 08:00AM	BioVie Announces First Patient Enrolled in BIV201 Phase 2b Clinical Trial for Ascites GlobeNewswire
Jun-23-21 08:00AM	BioVie Receives FDA Guidance for Phase 3 Clinical Trial of BIV201 in HRS-AKI GlobeNewswire
Jun-17-21 04:05PM	BioVie Interview to Air on Bloomberg Television U.S. on the RedChip Money Report® GlobeNewswire
Jun-11-21 08:00AM	BioVie Announces Closing of Acquisition of BioPharma Assets from Privately Held NeurMedix GlobeNewswire +21.65%
May-12-21 08:00AM	BioVie Hosting Research & Development Day GlobeNewswire -7.74%
06:13AM	Moving Average Crossover Alert: BioVie (BIVI) Zacks
May-10-21 08:19AM	BioVie Announces Amended Terms for Asset Acquisition from Privately Held NeurMedix GlobeNewswire
Apr-28-21 07:00AM	BioVie to Present at 2021 B. Riley Securities Neuroscience Conference GlobeNewswire -12.19%
Apr-27-21 04:05PM	BioVie Acquires Biopharma Assets from Privately Held NeurMedix GlobeNewswire
Mar-11-21 07:00AM	BioVie to Present at 31st Annual Oppenheimer Healthcare Conference GlobeNewswire +8.09%
Mar-09-21 07:00AM	BioVie Commences Patient Screening in Phase 2 Clinical Trial GlobeNewswire +31.42%
Feb-19-21 07:00AM	BioVie Interview to Air on Bloomberg TV in the US on the RedChip Money Report® GlobeNewswire +25.42%
Feb-02-21 08:30AM	NeurMedix Obtains FDA Authorization for Pivotal Phase 3 Alzheimers Trial GlobeNewswire +5.31%
Oct-30-20 08:00AM	BioVie Interview to Air on Bloomberg International on the RedChip Money Report GlobeNewswire
Oct-29-20 08:00AM	BioVie to Participate in B. Riley Securities Liver Disease Therapeutics Day on October 29, 2020 GlobeNewswire
Sep-23-20 08:00AM	BioVie Announces Closing of Public Offering of Common Stock GlobeNewswire
Sep-21-20 07:00AM	BioVie to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech Summit ACCESSWIRE
Sep-17-20 07:55PM	BioVie Inc. Announces Nasdaq Listing and Pricing of $15.7 Million Public Offering ACCESSWIRE -20.38%
Jun-16-20 08:30AM	Highly Accomplished Executives Join BioVies Board of Directors GlobeNewswire
Jun-11-20 08:30AM	BioVie Advances the BIV201 Clinical Program and Prefilled Syringe GlobeNewswire
Dec-09-19 08:00AM	BioVie Manufactures Novel Terlipressin Prefilled Syringe GlobeNewswire
Oct-22-19 07:00AM	BioVie Submits Protocol for Phase 2b/3 Refractory Ascites Study to FDA ACCESSWIRE +20.00%

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Santa Monica, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KIM JOANNE WENDY	CFO	Dec 07	Buy	5.40	2,000	10,798	2,000	Dec 09 04:46 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience